When MAR-5A3 was administered on day 4 after WNV-NY infection and splenocytes analyzed on day 9, we also observed a decrease in surface expression of CD86 on CD11b+ (P<0.05) and CD11c+ (P<0.007) cells relative to the control MAb treatment (Figure 5A and C). The gene discussed is ITGAM; the disease is infection.